Literature DB >> 8791980

The entero-insular axis in polycystic ovarian syndrome.

R Gama1, F Norris, J Wright, L Morgan, S Hampton, S Watkins, V Marks.   

Abstract

We investigated the contributions made by the entero-insular axis, proinsulin and the fractional hepatic extraction of insulin to the hyperinsulinaemia characteristic of polycystic ovarian syndrome (PCOS). We measured plasma glucose, gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (7-36 amide) (GLP-1(7-36) amide), immunoreactive insulin (IRI), intact proinsulin (IPI), and C-peptide concentrations during a 75 g oral glucose tolerance test in seven normal weight women with PCOS and eight healthy women. Women with PCOS had higher fasting (P = 0.05) and integrated (P < 0.01) IRI concentrations than controls. Fasting C-peptide levels were similar in both groups but integrated C-peptide (P < 0.05) concentrations were greater in PCOS subjects than controls. Fasting and integrated concentrations of glucose, GIP and GLP-1(7-36) amide were similar in subjects with PCOS and controls. Although fasting IPI concentrations were similar in both groups, integrated IPI concentrations were higher (P = 0.05) in patients with PCOS. Women with PCOS had similar fasting but higher (P < 0.05) integrated IRI:C-peptide molar ratios than controls. Fasting and integrated IPI:IRI molar ratios were similar in both groups. These results confirm that lean women with PCOS have peripheral hyperinsulinaemia. The mild fasting hyperinsulinaemia is due to increased pancreatic secretion, whereas the stimulated hyperinsulinaemia is due to both pancreatic hypersecretion and reduced fractional hepatic extraction of insulin. Hyperproinsulinaemia is modest and appropriate in PCOS, GIP and GLP-1(7-36) amide do not contribute to the stimulated hyperinsulinaemia in PCOS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791980     DOI: 10.1177/000456329603300303

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  5 in total

Review 1.  Gastrointestinal hormones and polycystic ovary syndrome.

Authors:  Jing Ma; Tzu Chun Lin; Wei Liu
Journal:  Endocrine       Date:  2014-05-04       Impact factor: 3.633

2.  An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity.

Authors:  Simona Ferjan; Mojca Jensterle; Tjasa Oblak; Irena Prodan Zitnik; Janja Marc; Katja Goricar; Vita Dolzan; Andrej Janez
Journal:  J Int Med Res       Date:  2019-08-23       Impact factor: 1.671

Review 3.  Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives.

Authors:  Mojca Jensterle; Rok Herman; Andrej Janež
Journal:  Biomedicines       Date:  2022-08-16

4.  Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome.

Authors:  Dorte Glintborg; Hanne Mumm; Jens Juul Holst; Marianne Andersen
Journal:  Endocr Connect       Date:  2017-04-21       Impact factor: 3.335

5.  Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.

Authors:  Tao Tao; Peihong Wu; Yuying Wang; Wei Liu
Journal:  BMC Endocr Disord       Date:  2018-02-27       Impact factor: 2.763

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.